# US 2012/0231448 A1 · Low cell toxicity antibiotic hygromycin b

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0231448 A1
- Document ID: US20120231448A1
- Status: Published application
- Kind: A1
- Application number: 13/414,056
- Filed: 2012-03-07
- Published: 2012-09-13
- Earliest claimed: 2011-03-08
- Assignees: TOKU-E Company
- Inventors: Qiubao PAN
- Web page: https://patentgrep.com/patent/US20120231448A1

## CPC

- C07H 15/224: with only one saccharide radical directly attached to the cyclohexyl radical, e.g. destomycin, fortimicin, neamine
- A61K 31/7048: having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin {, digitoxin or digoxin}
- A61P 31/04: Antibacterial agents
- C07H 1/08: from natural products
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A preparation of antibiotic hygromycin B with low cell toxicity and high purity, and methods of preparing such a preparation, are provided. More specifically, an isolated antibiotic hygromycin B with a purity of greater than 98% and impurities C, D and E individually less than 0.5% and impurity F less than 2%, as measured by HPLC, is described. Uses of this high purity antibiotic hygromycin B include, for example, for in vitro cell selection.

## Claims

### Claim 1

An isolated antibiotic hygromycin B with low cell toxicity having a purity of greater than 98% and impurities C, D and E individually less than 0.5% and impurity F less than 2%, wherein the purity and the impurities are measured by high performance liquid chromatography (HPLC), and hygromycin B having formula I:
where R of formula I is CH3 in hygromycin B;
wherein impurity F having formula I where R is H;
wherein impurity D having formula II:
and
wherein impurities C and E having formula III:
where R of formula III is H in impurity C, and R of formula III is CH3 in impurity E.

### Claim 2 (depends on 1)

The isolated antibiotic hygromycin B of claim 1 in combination with a carrier or diluent acceptable to one or more cell type.

### Claim 3 (depends on 1)

A method of producing antibiotic hygromycin B with low cell toxicity having a purity of greater than 98% and impurities C, D and E individually less than 0.5% and impurity F less than 2%, wherein the purity and the impurities are measured by HPLC, and hygromycin B and impurities C, D, E and F having the formulae according to claim 1, comprising the steps of:
(a) dissolving hygromycin B, having purity of 83% up to 98% by HPLC, in sufficient water to make a 50% (w/v) solution;
(b) exposing the solution of step (a) to silica gel loaded into a column which is maintained at 20° C., wherein the silica gel has been balanced with standard pH 8 phosphoric buffer;
(c) contacting the silica gel of step (b) with additional standard pH 8 phosphoric buffer to elute destomic acid (6.9 minutes), impurity C (6.9 minutes) and impurity D (7.1 minutes);
(d) contacting the silica gel of step (c) with standard pH 8 phosphoric buffer at three times the standard concentration at a flow rate of 25 ml/minute to elute impurity E and impurity F;
(e) repeating step (d) for ten bed volumes, or greater if monitoring for impurities by HPLC warrants; and
(f) contacting the silica gel of step (e) with 0.05 M HCl to desorb hygromycin B, thereby yielding hygromycin B with a purity of greater than 98% as measured by HPLC.

### Claim 4 (depends on 3)

The method of claim 3 with further step (g) comprising removing chloride from the hygromycin B of step (f) by anion ion exchange.

### Claim 5 (depends on 4)

The method of claim 4 with further step (h) comprising converting the hygromycin B of step (g) to a dry state.
